PKR regulates proliferation, differentiation, and survival of murine hematopoietic stem/progenitor cells

Blood

Volumn 121, Issue 17, 2013, Pages 3364-3374

  Liu, Xiangfei ^a   Bennett, Richard L ^a   Cheng, Xiaodong ^a   Byrne, Michael ^a   Reinhard, Mary K ^b   May, W Stratford ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b University of Florida College of Veterinary Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; HEMOGLOBIN; INITIATION FACTOR 2ALPHA; INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE R; PROTEIN P21; CYTOKINE; MESSENGER RNA;

AGE; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW DISEASE; CELL AGING; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; CELL SELF-RENEWAL; CELL STRESS; CELL SURVIVAL; COLONY FORMING UNIT; CONTROLLED STUDY; GENE EXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC TISSUE; HEMOGLOBIN BLOOD LEVEL; IN VITRO STUDY; LEUKOCYTE COUNT; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THROMBOCYTE COUNT; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL CYCLE; CYTOLOGY; DOMINANT GENE; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; RADIATION DOSE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW DISEASES; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; EIF-2 KINASE; FEMALE; FLOW CYTOMETRY; GENES, DOMINANT; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RADIATION TOLERANCE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

MLCS; MLOWN;

EID: 84877594165     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-456400     Document Type: Article

References (26)

1. Blalock WL, Weinstein-Oppenheimer C, Chang F, et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia. 1999;13(8): 1109-1166.
2. Hapel AJ, Fung MC, Johnson RM, et al. Biologic properties of molecularly cloned and expressed murine interleukin-3. Blood. 1985;65(6): 1453-1459.
3. Matsumoto A, Nakayama KI. Role of key regulators of the cell cycle in maintenance of hematopoietic stem cells. Biochim Biophys Acta. 2013;1830(2):2335-2344.
4. Liesveld JL, Jordan CT, Phillips GL II. The hematopoietic stem cell in myelodysplasia. Stem Cells. 2004;22(4):590-599.
5. Lécuyer E, Hoang T. SCL: from the origin of hematopoiesis to stem cells and leukemia. Exp Hematol. 2004;32(1):11-24.
6. Bennett RL, Blalock WL, Abtahi DM, et al. RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection. Blood. 2006;108(3):821-829.
7. Ito T, Yang M, May WS. RAX, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling. J Biol Chem. 1999; 274(22):15427-15432.
8. Ito T, Jagus R, May WS. Interleukin 3 stimulates protein synthesis by regulating double-stranded RNA-dependent protein kinase. Proc Natl Acad Sci USA. 1994;91(16):7455-7459.
9. Williams BR. PKR; a sentinel kinase for cellular stress. Oncogene. 1999;18(45):6112-6120.
10. Colli ML, Nogueira TC, Allagnat F, et al. Exposure to the viral by-product dsRNA or Coxsackievirus B5 triggers pancreatic beta cell apoptosis via a Bim / Mcl-1 imbalance. PLoS Pathog. 2011;7(9): e1002267.
11. Wong AH, Tam NW, Yang YL, et al. Physical association between STAT1 and the interferon-inducible protein kinase PKR and implications for interferon and double-stranded RNA signaling pathways. EMBO J. 1997;16(6):1291-1304.
12. 1 arrest. Cell Cycle. 2012;11(2):407-417.
13. Murad JM, Tone LG, de Souza LR, et al. A point mutation in the RNA-binding domain I results in decrease of PKR activation in acute lymphoblastic leukemia. Blood Cells Mol Dis. 2005;34(1):1-5.
14. Savinova O, Joshi B, Jagus R. Abnormal levels and minimal activity of the dsRNA-activated protein kinase, PKR, in breast carcinoma cells. Int J Biochem Cell Biol. 1999;31(1):175-189.
15. Hii SI, Hardy L, Crough T, et al. Loss of PKR activity in chronic lymphocytic leukemia. Int J Cancer. 2004;109(3):329-335.
16. Barber GN, Wambach M, Thompson S, et al. Mutants of the RNA-dependent protein kinase (PKR) lacking double-stranded RNA binding domain I can act as transdominant inhibitors and induce malignant transformation. Mol Cell Biol. 1995;15(6):3138-3146.
17. Sharma B, Altman JK, Goussetis DJ, et al. Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis. J Biol Chem. 2011;286(31):27506-27514.
18. Follo MY, Finelli C, Mongiorgi S, et al. PKR is activated in MDS patients and its subcellular localization depends on disease severity. Leukemia. 2008;22(12):2267-2269.
19. Ogilvy S, Elefanty AG, Visvader J, et al. Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood. 1998;91(2):419-430.
20. Ogilvy S, Metcalf D, Gibson L, et al. Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood. 1999;94(6):1855-1863.
21. Kumar A, Yang YL, Flati V, et al. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-kappaB. EMBO J. 1997;16(2): 406-416.
22. Armstrong MJ, Stang MT, Liu Y, et al. Interferon Regulatory Factor 1 (IRF-1) induces p21(WAF1/ CIP1) dependent cell cycle arrest and p21(WAF1/ CIP1) independent modulation of survivin in cancer cells. Cancer Lett. 2012;319(1):56-65.
23. Ladiges W, Morton J, Hopkins H, et al. Expression of human PKR protein kinase in transgenic mice. J Interferon Cytokine Res. 2002;22(3):329-334.
24. Page TJ, MacWilliams PS, Suresh M, et al. 7-12 Dimethylbenz[a]anthracene-induced bone marrow hypocellularity is dependent on signaling through both the TNFR and PKR. Toxicol Appl Pharmacol. 2004;198(1):21-28.
25. Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009;6(11):627-637.
26. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med. 2005;56:1-16.